Cart
sales@molnova.com
PF 00356231
CAS No. 766536-21-4
PF 00356231( —— )
Catalog No. M28524 CAS No. 766536-21-4
PF 00356231 is a selectivity inhibitor MMP-12 and can be used in studies about the treatment of emphysema and chronic obstructive pulmonary disease (COPD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 393 | Get Quote |
|
| 10MG | 590 | Get Quote |
|
| 25MG | 1060 | Get Quote |
|
| 50MG | 1591 | Get Quote |
|
| 100MG | 2387 | Get Quote |
|
| 200MG | 3580 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF 00356231
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF 00356231 is a selectivity inhibitor MMP-12 and can be used in studies about the treatment of emphysema and chronic obstructive pulmonary disease (COPD).
-
DescriptionPF 00356231 is a selectivity inhibitor MMP-12 and can be used in studies about the treatment of emphysema and chronic obstructive pulmonary disease (COPD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetMMP
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number766536-21-4
-
Formula Weight428.51
-
Molecular FormulaC25H20N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(=O)CC(NC(=O)c1cc(cs1)-c1ccc(cc1)-c1ccncc1)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Rilpivirine HCl
Rilpivirine HCl (Rilpivirine hydrochloride) is a selective and potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with antiviral activity that inhibits the HIV virus and can be used in the study of HIV infections.
-
Bovine Type II Colla...
Bovine Type II Collagen (Collagen Type II,Bovine) is a homologous superhelical structure consisting of three identical α1(II) chains, and is a major component of animal cartilage.
-
Colistimethate Sodiu...
Colistimethate Sodium is used for the treatment of serious infections due to selected aerobic Gram-negative pathogens in patients with limited treatment options.
